Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志  2017, Vol. 37 Issue (3): 78-82    DOI: 10.13523/j.cb.20170311
综述     
人脐带间充质干细胞抗肿瘤机制的研究进展
陈文杰1,2,3, 汪建样4, 殷明2, 殷嫦嫦1
1. 九江学院基础医学院 九江市转化医学重点实验室 九江 332000;
2. 南昌大学第二附属医院 南昌 330006;
3. 南昌大学研究生院医学部 南昌 330006;
4. 九江市第一人民医院 九江 332000
Progress on Anti-cancer Molecule Mechanism of Human Umbilical Cord Mesenchymal Stem Cells
CHEN Wen-jie1,2,3, WANG Jian-yang4, YIN Ming2, YIN Chang-chang1
1. Jiujiang Key Laboratory of Translational Medicine, Basic Medical College, Jiujiang University, Jiujiang 332000, China;
2. The Second Hospital Afficiated of Nanchang University, Nanchang 330006, China;
3. Medicine School of Graduate Center, Nanchang University, Nanchang 330006, China;
4. The first hospital of Jiujiang, Jiujiang 332000, China
 全文: PDF(480 KB)   HTML
摘要:

人脐带间充质干细胞(HUMSCs)是一种具有高度自我更新能力和多向分化潜能的干细胞群,具有分泌特定细胞因子、诱导肿瘤细胞凋亡、适用于基因编辑、安全性好及肿瘤趋向性等特性。有较多的研究者研究HUMSCs对肿瘤的作用,试图将HUMSCs作为肿瘤治疗的新方法。就HUMSCs抗肿瘤作用的研究进展作一综述。

关键词: 肿瘤趋向性人脐带间充质干细胞抗肿瘤    
Abstract:

HUMSCs is a stem cell population with high self-renewal capcity and multiple differention potential.They have secret special cytokine,induce apoptosis of tumor,migrate to tumor cells,adapt on gene editing and safety properties.Regarding their therapic value,many researchs use HUMSCs as cell-based treatment in tumor.The anti-tumor effect of HUMSCs is critically elaborated.

Key words: HUMSCs    Tumor tropism    Anti-tumor
收稿日期: 2016-09-26 出版日期: 2017-03-25
ZTFLH:  Q819  
基金资助:

国家自然科学基金资助项目(81160226)

通讯作者: 殷嫦嫦     E-mail: yinming0791@aliyun.com
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  

引用本文:

陈文杰, 汪建样, 殷明, 殷嫦嫦. 人脐带间充质干细胞抗肿瘤机制的研究进展[J]. 中国生物工程杂志, 2017, 37(3): 78-82.

CHEN Wen-jie, WANG Jian-yang, YIN Ming, YIN Chang-chang. Progress on Anti-cancer Molecule Mechanism of Human Umbilical Cord Mesenchymal Stem Cells. China Biotechnology, 2017, 37(3): 78-82.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20170311        https://manu60.magtech.com.cn/biotech/CN/Y2017/V37/I3/78

[1] 杨跃梅,沈倍奋.靶向抗肿瘤抗体一药物偶联物研究进展. 国际药学研究杂志, 2014,41(1):15-50. Yang Y M,Shen B F. Development of antibody-drug conjugates as targeted cancer therapeutics. Journal of International Pharmaceutical Research. 2014,41(1):15-50.
[2] Li Z, Fan D, Xiong D.Mesenchymal stem cells as delivery vectors for anti-tumor therapy. Stem Cell Investig.[2017-02-14]. http://sci.amegroups.com/article/view/5978/6693.
[3] Ding D C, Chang Y H, Shyu W C,et al. Human umbilical cord mesenchymal stem cells:a new era for stem cell therapy. Cell Transplant, 2015,24(3):339-347.
[4] 方洪松,周建林,彭昊,等. 不同来源间充质干细胞生物学特性差异. 中国组织工程研究, 2015,19(32):5243-5248. Fang H S,Zhou J L,Peng H,et al. Biological characteristics of different sources of mesenchymal stem cells. Journal of Clinical Rehabilitative Tissue Engineering Research, 2015,19(32):5243-5248.
[5] Nowakowski A, Walczak P, Janowski M,et al. Genetic engineering of mesenchymal stem cells for regenerative medicine. Stem Cells Dev, 2015,24(19):2219-2242.
[6] Nowakowski A, Walczak P, Lukomska B, et al. Genetic engineering of mesenchymal stem cells to induce their migration and survival. Stem Cell International in press.[2017-02-14]. https://www.hindawi.com/journals/sci/2016/4956063/.
[7] Gauthaman K, Fong C Y, Cheyyatraivendran S, et al. Extra-embryonic human Wharton's jelly stem cells do not induce tumorigenesis, unlike human embryonic stem cells. Reprod Biomed Online, 2012,24(2):235-246.
[8] Ganta C, Chiyo D, Ayuzawa R, et al. Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Res, 2009,69(5):1815-1820.
[9] Ding D C,Shyu W C,Lin S Z. Mesenchymal stem cells.Cell Transplant,2011,20(1):5-14.
[10] Yan C H, Yang M,Li Z Z, et al.Suppressionof orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter. Biomaterials, 2014,35(9):3035-3043.
[11] Rachakatla R S, Marini F, Weiss M L,et al. Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther, 2007,14(10):828-835.
[12] 胡文龙,吴平平,耿书国,等. 人脐带间充质干细胞分泌白细胞介素6促进骨肉瘤细胞增殖和迁移. 中国病理生理杂志, 2016, 32(2):201-207. Hu W L,Wu P P,Geng S G,et al. Chinese Journal of Pathophysiology, 2016,32(2):201-207.
[13] Dittmar T, Entschladen F.Migratory properties of mesenchymal stem cells.Adv Biochem Eng Biotechnol, 2013,129:117-136.
[14] Janssen A, Medema R H. Entosis:aneuploidy by invasion. Nat Cell Biol, 2011,13(3):199-201.
[15] Wang M, Ning X, Chen A, et al. Impaired formation of homotypic cell-in-cell structures in human tumor cells lacking alpha-catenin expression.[2017-02-14].http://www.nature.com/articles/srep12223.
[16] Krishna S, Overholtzer M.Mechanisms and consequences of entosis.Cell Mol Life Sci, 2016,73(11-12):2379-2386.
[17] Chao K C, Yang H T, Chen M. Human umbilical cord mesenchymal stem cells suppress breast cancer tumourigenesis through direct cell-cell contact and internalization. J Cell Mol Med, 2012,16(8):1803-1815.
[18] Wolf P. The nature and signifiance of platelet products in human plasma. Br J Haematol, 1967,13(3):269-88.
[19] Im H, Shao H, Park Y I, et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor.Nature Biotechnology, 2014,32(5):490-495.
[20] Robbins P D, Morelli A E. Regulation of immune responses by extracellular vesicles. Nature Reviews Immunology, 2014,14(3):195-208.
[21] Lee J K, Park S R, Jung B K, et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by downregulating VEGF expression in breast cancer cells. PLoS One, 2013,8(12):e84256.
[22] Roccaro A M, Sacco A, Maiso P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. Journal of Clinical Investigation, 2013,123(4):1542-1555.
[23] Akyurekli C, Le Y, Richardson R B, et al. A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Reviews and Reports, 2015, 11(1):150-160.
[24] 王喜梅. 微囊泡在组织再生中的研究进展. 医学综述, 2012, 18(13):1993-1995. Wang X M. Research advances of microvesicles in tissue regeneration.Medical Recapitulate, 2012, 18(13):1993-1995.
[25] Akyurekli C, Le Y, Richardson R B, et al. A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Reviews and Reports, 2015, 11(1):150-160.
[26] Wu S, Ju G Q, Du T,et al. Microvesicles derived from human umbilical cord wharton's jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo.PLoS One, 2013,8(4):e61366.
[27] Yang C,Mwaikambo B R,Zhu T, et al. Lymphocytic microparticles inhibit angiogenesis by stimulating oxidative stress and negatively regulating VEGF-induced pathways. Am J Physiol Regul Integr Comp Physiol, 2008,294(2):R467-R476.
[28] Wong V L, Rieman D J, Aronson L,et al. Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines. Int J Cancer, 1989,43(3):526-530.
[29] Shen C J, Chan T F, Chen C C, et al.Human umbilical cord matrix-derived stem cells expressing interferon-β gene inhibit breast cancer cells via apoptosis. Oncotarget, 2016,7(23):34172-34179.
[30] Walczak H, Miller R E, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 1999,5(2):157-163.
[31] Yan C, Yang M, Li Z Z, et al.Suppressionof orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter. Biomaterials, 2014,35(9):3035-3043.

[1] 邓蕊,曾佳利,卢雪梅. 基于Musca domestica cecropin的抗肿瘤小分子衍生肽筛选及构效关系解析*[J]. 中国生物工程杂志, 2021, 41(11): 14-22.
[2] 杨威,宋方祥,王帅,张黎,王红霞,李焱. 药物输送系统中Janus纳米粒子的制备及应用 *[J]. 中国生物工程杂志, 2020, 40(7): 70-81.
[3] 童梅,程永庆,刘金毅,徐晨. 促进大肠杆菌周质空间小分子抗体表达的菌种构建方法*[J]. 中国生物工程杂志, 2020, 40(5): 48-56.
[4] 卢钟腾,呼高伟. 新型细胞穿膜肽的鉴定方法与其在抗肿瘤治疗中的应用[J]. 中国生物工程杂志, 2019, 39(12): 50-55.
[5] 李思,翟逸舟,陆玉婷,王富军,赵健. 一种用于肿瘤药物治疗的新型人源性穿膜肽的优化及其应用 *[J]. 中国生物工程杂志, 2018, 38(7): 40-49.
[6] 刘立平, 张纯, 殷爽, 王祺, 张耀, 余蓉, 刘永东, 苏志国. 白蛋白结合肽-多柔比星耦合物的设计、制备、表征及初步评价[J]. 中国生物工程杂志, 2017, 37(4): 68-75.
[7] 李敏, 吴日伟. 抗肿瘤药物市场概述[J]. 中国生物工程杂志, 2017, 37(4): 125-133.
[8] 陈坤, 曹雪玮, 张琴, 赵健, 王富军. EGF类生长因子来源的新型靶向肽在抗肿瘤药物蛋白中的应用[J]. 中国生物工程杂志, 2017, 37(3): 1-9.
[9] 李娅莎, 刘星, 毕杨, 杨珂, 赵丽, 龚梦嘉, 郭绮. BMP9诱导人脐带间充质干细胞体内外成骨分化的作用研究[J]. 中国生物工程杂志, 2016, 36(5): 20-26.
[10] 雷良欢, 黄同龙, 魏慧, 廖继燕, 吴雨婧, 周偲, 夏立秋, 张友明. 叶柄粘球菌STXZ77的分离鉴定及抗肿瘤活性[J]. 中国生物工程杂志, 2016, 36(11): 7-15.
[11] 周立军, 刘文娟, 祁永浩, 李妙. SOCS3通过JNK和STAT3信号通路调控AKT[J]. 中国生物工程杂志, 2015, 35(9): 50-56.
[12] 王世奇, 刘婧莹, 刘晨浪, 李纯, 胡晓凤, 夏立秋, 张友明. sTRAIL蛋白原核表达载体的构建、表达及抗肿瘤活性研究[J]. 中国生物工程杂志, 2015, 35(12): 1-7.
[13] 文也, 唐少军, 肖蓉, 丁学知, 黄同龙, 雷良欢, 夏立秋. 粘细菌Myxococcus macrosporus STXZ54抗肿瘤活性物质的分离制备及其活性测定[J]. 中国生物工程杂志, 2014, 34(9): 63-71.
[14] 陈悦, 付中平, 李景荣, 殷晓进. 重组蛋白ES-Kringle5的表达、纯化及活性检测[J]. 中国生物工程杂志, 2014, 34(5): 60-65.
[15] 王启帆, 薛莹, 冯新为, 张革. 靶向抗肿瘤蛋白iRGD-CDD的原核表达及生物活性鉴定[J]. 中国生物工程杂志, 2014, 34(12): 1-9.